Turnstone Biologics Inc. (acquired by Xoma Royalty)

Home Investment Portfolio Turnstone Biologics Inc. (acquired by Xoma Royalty)

Innovation Type:

Therapeutics

Cancer Type:

Multiple

Funding Stage:

Exit

Fund:

Compass Rose

Developing next-generation tumor infiltrating lymphocytes (TIL) therapies by selecting the most potent and tumor-reactive T cells for potential treatment across multiple solid tumors

Related news

FACIT founded Turnstone Biologics debuts on Nasdaq market

FACIT congratulates Turnstone Biologics on the announcement of their upsized initial public offering (IPO) and debut on the Nasdaq market. Read More

FACIT Features: Turnstone Biologics completes oversubscribed $80M USD Series D Financing

July 21, 2021 – The start-up seeded by FACIT in collaboration with several Ontario research institutes continues to deepen its roots in Canada and grow on both sides of the border. Read More

Turnstone Biologics Announces Enrollment in Landmark Oncolytic Vaccine Trial

Turnstone Biologics Inc., a FACIT portfolio company, has announced the ongoing enrollment of the Marabex™ clinical trial assessing the safety and immune responses in patients with advanced or metastatic, MAGE-A3-expressing solid tumours. Read More

Turnstone Biologics Inc. to Accelerate Clinical and Commercial Translation of Cancer Immunotherapies

FACIT and its partners are pleased to announce the formation of Turnstone Biologics Inc., a biotechnology company focussed on developing treatments for cancer that harness the patient’s own immune system. Read More

FACIT Features: Turnstone and AbbVie Announce Collaboration

Turnstone Biologics, a startup co-founded by FACIT, announced a research, option and license agreement with AbbVie Inc. for up to three of Turnstone's next-gen oncolytic viral immunotherapies. This partnership deepens the Ontario roots established by FACIT and its co-founders, expanding the scale of innovative research and local career opportunities for scientists. Read More

FACIT Start-up Turnstone Biologics Closes USD $41M Financing

FACIT-created Turnstone Biologics raises USD $41M, one of the largest Series B rounds for a Canadian biotech, attracting blue-chip healthcare investors to accelerate commercialization of proprietary oncolytic viral immunotherapies. Read More

FACIT Startup Turnstone Biologics Closes $11M Financing, Secures Additional Capital Commitment, and Adds Strong Management

Versant Ventures-led investment accelerates development, broadens oncolytic viral immunotherapy potential. Read More

First Patient Treated in Turnstone's Lung Cancer Trial Combining Novel Viral Cancer Therapy with Approved Checkpoint Inhibitor

Turnstone announced that treatment has been initiated on the first patient in the company's Phase I/II clinical trial combining its novel oncolytic viral immunotherapy agent, MG1-MAGEA3, with pembrolizumab, an approved anti-PD-1 antibody. Read More